Virax Biolabs Group

VRAXNasdaq United Kingdom Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$3.430 M

$2.55 +2.00%

Close of 23 Sept 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

579,218

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances, ranked by market cap

All 19 →

#15Q/C TechnologiesQCLS$7.20M
#16VolitionrxVNRX$6.89M
#17Trinity BiotechTRIB$5.70M
#18Cardio DiagnosticsCDIO$5.68M
#19Virax Biolabs GroupVRAX$3.43M

What if Virax Biolabs Group were worth as much as…

Open the what-if tool →

Gold $29.8T

$22,191,224

Per share 8,702,441× higher

Bitcoin $1.69T

$1,259,580

Per share 493,953× higher

Nvidia $5.43T

$4,040,773

Per share 1,584,617× higher

Or at a round number

$5.00M $10.0M $20.0M $50.0M

Where these numbers come from

Share counts and financials for Virax Biolabs Group are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 24 Sept 2026. Read the methodology.